Exudative age-related macular degeneration (AMD) treatments involve intravitreal injections, while no successful treatments exist for nonexudative AMD.

Exudative versus Nonexudative Age-Related Macular Degeneration: Physiopathology and Treatment Options

Pharmacological advances in treating age-related macular degeneration have improved, but more clinical trials and safety studies are needed to optimize treatment for dry and wet AMD.

Pharmacological advances in the treatment of age-related macular degeneration.

Subthreshold nanosecond laser treatment may slow progression in intermediate age-related macular degeneration for those without coexistent reticular pseudodrusen, but may be inappropriate for those with this condition.

Subthreshold Nanosecond Laser Intervention in Age-Related Macular Degeneration: The LEAD Randomized Controlled Clinical Trial.

Current treatments for age-related macular degeneration focus on blocking VEGF, while future treatments aim to prevent vision loss due to scarring and address the dry form of the disease.

CURRENT KNOWLEDGE AND TRENDS IN AGE-RELATED MACULAR DEGENERATION: Today’s and Future Treatments

There are promising treatments for dry AMD and STGD, but more high-quality research is needed to confirm their effectiveness and inform future NIHR research.

Treatments for dry age-related macular degeneration and Stargardt disease: a systematic review.

Traditional Chinese medicine (TCM) shows promise in treating age-related macular degeneration, but more rigorous scientific evidence is needed to enhance its impact and uptake.

Non-neglectable therapeutic options for age-related macular degeneration: A promising perspective from traditional Chinese medicine.

Nanotechnology and gene therapy strategies show promise in reducing treatment burden and improving visual effects for age-related macular degeneration.

Nanotechnology for Age-Related Macular Degeneration

Neovascular age-related macular degeneration treatment advances have improved, but new approaches like DARPins show promise for maintaining vision and enhancing patient compliance.

Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches

Neovascular age-related macular degeneration treatment advances include reducing intravitreal injections and combining anti-VEGF therapies with other treatments to improve visual outcomes and reduce treatment burden.

Current advances in the treatment of neovascular age-related macular degeneration

Emerging therapies for age-related macular degeneration show promise for improving patient experience and reducing complications, but require improved delivery methods and sustainability of clinical effects for non-neovascular cases.

Emerging therapies and their delivery for treating age‐related macular degeneration

Clinical trials for therapies aimed at slowing or reversing dry age-related macular degeneration show promising progress, but more research is needed to develop a successful treatment.

Progress of clinical therapies for dry age-related macular degeneration.

Nanotechnology and 3D bioprinting show potential in treating age-related macular degeneration without intravitreal injections and reducing adverse effects.

Therapeutic Approaches for Age-Related Macular Degeneration

Nanotherapeutics offer a promising alternative for treating age-related macular degeneration by enhancing bioactivity, improving bioavailability, and ensuring sustained release of drugs across ocular tissues.

Emerging innovations in nano-enabled therapy against age-related macular degeneration: A paradigm shift.

Emerging therapeutic options, such as steroids and encapsulated cell technology, may help overcome limitations of current anti-VEGF therapy and extend the duration of effects in age-related macular degeneration.

Emerging Therapeutic Options in Age-Related Macular Degeneration

Dry age-related macular degeneration (dAMD) treatment options include complement pathway inhibitors, visual cycle modulators, and antioxidative therapy, with potential for reducing geographic atrophy progression.

Treatment of dry age‐related macular degeneration: A review

Age-related macular degeneration is a multifactorial disorder with genetic and non-genetic risk factors, and treatment varies depending on the stage and treatment options.

Age-related macular degeneration

Emerging therapies show promise for improving age-related macular degeneration treatment, with promising results expected within the next decade.

Emerging biological therapies for the treatment of age-related macular degeneration

Cell therapy and biomaterial-based therapies show promise for treating age-related macular degeneration, offering a promising alternative to drug-based treatments and improving survival and integration of implanted cells.

Biotechnology and Biomaterial-Based Therapeutic Strategies for Age-Related Macular Degeneration. Part II: Cell and Tissue Engineering Therapies

Dry age-related macular degeneration (AMD) treatment options include antioxidative drugs, complement inhibitors, neuroprotective agents, visual cycle inhibitors, gene therapy, and cell-based therapies, with promising results in early phase clinical trials.

Treatments for dry age-related macular degeneration: therapeutic avenues, clinical trials and future directions

Exosomes show promising results in preserving retinal function and morphology, and protecting photoreceptors from apoptosis in age-related macular degeneration animal models.

Extracellular vesicles as a potential therapeutic for age-related macular degeneration

What are the latest treatments for age-related macular degeneration?

These studies suggest that the latest treatments for age-related macular degeneration include intravitreal injections, VEGF blockers, subthreshold nanosecond laser treatment, nanotechnology, gene therapy, and traditional Chinese medicine, with ongoing research to improve and confirm their effectiveness.